Skip to Content

Oriahnn Approval History

FDA Approved: Yes (First approved May 29, 2020)
Brand name: Oriahnn
Generic name: elagolix/estradiol/norethindrone acetate and elagolix
Dosage form: Capsules
Company: AbbVie Inc.
Treatment for: Uterine Leiomyomata

Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estrogen and progestin co-formulation indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Development History and FDA Approval Process for Oriahnn

DateArticle
May 29, 2020Approval FDA Approves Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-Menopausal Women

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.